Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs

Vaccine

Volumn 23, Issue 46-47, 2005, Pages 5424-5431

  Prichard, Mark N ^a,b   Kaiwar, Ravi ^a,c   Jackman, Winthrop T ^a   Quenelle, Debra C ^b   Collins, Deborah J ^b   Kern, Earl R ^b   Kemble, George M ^a   Spaete, Richard R ^a  

^a MEDIMMUNE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Novacea Inc   (United States)

Author keywords

Attenuated vaccine; Genital herpes; Guinea pig; Herpesvirus vaccine; HSV 2

Indexed keywords

AD 472; HERPES SIMPLEX VACCINE; LIVE VACCINE; RECOMBINANT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; FEMALE; GENE CONSTRUCT; GENE DELETION; GENETIC ENGINEERING; GENITAL HERPES; GUINEA PIG; HERPES SIMPLEX VIRUS 2; IMMUNIZATION; INFECTION PREVENTION; LATENT PERIOD; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROVOCATION TEST; VAGINA; VIRAL GENETICS; VIRUS ACTIVATION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; FEMALE; GUINEA PIGS; HERPES GENITALIS; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 2, HUMAN; HUMANS; NEUTRALIZATION TESTS; PHENOTYPE; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VAGINA; VIRUS REPLICATION;

EID: 27644585820     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.02.028     Document Type: Article

References (25)

1. M.E. Boursnell, C. Entwisle, D. Blakeley, C. Roberts, I.A. Duncan, and S.E. Chisholm A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease J Infect Dis 175 1997 16 25
2. Z.A. Brown, A. Wald, R.A. Morrow, S. Selke, J. Zeh, and L. Corey Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant JAMA 289 2003 203 209
3. Cadoz M, Micoud M, Seigneurin J, et al. Presented at the program and abstracts for the 32nd interscience conference on antimicrobial agents and chemotherapy. Anaheim, CA; 1992.
4. 134.5 genes precludes shutoff of protein synthesis by blocking the phosphorylation of eIF-2alpha J Virol 72 1998 7005 7011
5. J. Chou, E.R. Kern, R.J. Whitley, and B. Roizman Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture Science 250 1990 1262 1266
6. L. Corey, A.G. Langenberg, R. Ashley, R.E. Sekulovich, A.E. Izu, and J.M. Douglas Jr. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group JAMA 282 1999 331 340
7. L. Corey, and P.G. Spear Infections with herpes simplex viruses (1) N Engl J Med 314 1986 686 691
8. L. Corey, A. Wald, R. Patel, S.L. Sacks, S.K. Tyring, and T. Warren Once-daily valacyclovir to reduce the risk of transmission of genital herpes N Engl J Med 350 2004 11 20
9. C. Domingo, I. Gadea, M. Pardeiro, C. Castilla, S. Fernandez, and M.A. Fernandez-Clua Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D Vaccine 21 2003 3565 3574
10. D.T. Fleming, G.M. McQuillan, R.E. Johnson, A.J. Nahmias, S.O. Aral, and F.K. Lee Herpes simplex virus type 2 in the United States, 1976 to 1994 N Engl J Med 337 1997 1105 1111
11. 134.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene J Virol 71 1997 6049 6054
12. E.R. Kern Acyclovir treatment of experimental genital herpes simplex virus infections Am J Med 73 1982 100 108
13. E.R. Kern, J.C. Overall Jr., and L.A. Glasgow Herpesvirus hominis infection in newborn mice. I. An experimental model and therapy with iododeoxyuridine J Infect Dis 128 1973 290 299
14. D.W. Kimberlin Neonatal herpes simplex infection Clin Microbiol Rev 17 2004 1 13
15. D.M. Koelle, and L. Corey Recent progress in herpes simplex virus immunobiology and vaccine research Clin Microbiol Rev 16 2003 96 113
16. B. Kuter, H. Matthews, H. Shinefield, S. Black, P. Dennehy, and B. Watson Ten year follow-up of healthy children who received one or two injections of varicella vaccine Pediatr Infect Dis J 23 2004 132 137
17. C.S. McLean, M. Erturk, R. Jennings, D.N. Challanain, A.C. Minson, and I. Duncan Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1 J Infect Dis 170 1994 1100 1109
18. B. Meignier, R. Longnecker, and B. Roizman In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents J Infect Dis 158 1988 602 614
19. M. Reitano, S. Tyring, W. Lang, C. Thoming, A.M. Worm, and S. Borelli Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group J Infect Dis 178 1998 603 610
20. F.C. Spector, E.R. Kern, J. Palmer, R. Kaiwar, T.A. Cha, and P. Brown Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs J Infect Dis 177 1998 1143 1154
21. L.R. Stanberry, A.L. Cunningham, A. Mindel, L.L. Scott, S.L. Spruance, and F.Y. Aoki Prospects for control of herpes simplex virus disease through immunization Clin Infect Dis 30 2000 549 566
22. L.R. Stanberry, E.R. Kern, J.T. Richards, T.M. Abbott, and J.C. Overall Jr. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease J Infect Dis 146 1982 397 404
23. L.R. Stanberry, S.L. Spruance, A.L. Cunningham, D.I. Bernstein, A. Mindel, and S. Sacks Glycoprotein-d-adjuvant vaccine to prevent genital herpes N Engl J Med 347 2002 1652 1661
24. 1 34.5 deletion mutants in rodent models J Clin Invest 91 1993 2837 2843
25. R.J. Whitley, and B. Roizman Herpes simplex virus infections Lancet 357 2001 1513 1518